This 2020 pharmacovigilance study analyzed data from the FDA Adverse Event Reporting System (FAERS) to assess cardiovascular safety signals associated with antiobesity medications. The researchers focused on drugs including lorcaserin, phentermine, orlistat, and naltrexone/bupropion. Findings indicated that lorcaserin was associated with reports of valvulopathy and cardiac disorders, while phentermine was
